Zoetis Inc.

"Sales to our largest customer, a U.S. veterinary distributor, represented approximately 16% of total revenue for 2025."

"Per XBRL (Segment Information - Income Statement (Details)): United States represented 53.8% of disclosed total revenue."

"Certain third-party suppliers may be the sole or exclusive source of certain products, materials and services necessary for production of our products."

"For example, our five top-selling products and product lines, Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela and our ceftiofur line, contributed approximately 42% of our revenue in 2025, and certain issues with these top-selling products and product lines could have a more significant impact to our results of operations."

"No credit concentration disclosure was detected in the most recent filing parsed."